Akums Drugs and Pharmaceuticals has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a standalone profit of ₹151.97 million for the quarter. Demonstrating strong commitment to shareholder value, the Board has recommended a final dividend of ₹1.00 per share and a special dividend of ₹2.00 per share, with the record date for entitlement fixed for July 3, 2026.
Financial Performance Review
For the financial year ended March 31, 2026, Akums Drugs and Pharmaceuticals posted a standalone profit of ₹1,116.40 million. The company’s total revenue from operations for the full year stood at ₹13,487.36 million. On a consolidated basis, the Group performed strongly, reporting an annual profit of ₹2,563.97 million with consolidated revenues reaching ₹43,590.17 million.
Dividend Recommendations
The Board of Directors has recommended a robust dividend package for the shareholders, subject to approval at the 22nd Annual General Meeting. This includes a final dividend of ₹1.00 per equity share and an additional special dividend of ₹2.00 per equity share, both on shares with a face value of ₹2. The company has fixed July 3, 2026, as the ‘Record Date’ for determining shareholder eligibility.
Corporate Developments and Leadership Changes
The company announced strategic changes to its senior management team, effective May 14, 2026. Mr. V Jagannathan has been appointed as the new President – HR, succeeding Mr. Arvind Srivastava, who is stepping down due to internal structural shifts. Additionally, the company has appointed Mahajan & Aibara LLP as its internal auditors for the 2026-27 financial year, and re-appointed M/s. Balwinder & Associates as cost auditors.
Annual General Meeting
The 22nd Annual General Meeting of the company is scheduled to take place on Friday, July 10, 2026, at 11:00 AM IST. The meeting will be conducted through video conferencing and other audio-visual means to ensure shareholder participation.
Source: BSE
